Track record · closed signal

Danaher Corporation (DHR) — closed signal from October 21, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 19, 2026 — +5.1% at the close.

Predicted vs. what happened

DHR price · publication thesis → realized outcomesplit-adjusted

$221.39 – $225.38Entry zone — fair-value band

$224.61Published — price the day we called it

$257.95Target — the price the thesis aimed for

$241.26Peak — highest point inside the window, not a realized return

$235.99Window close — end-of-window price, context only

What happened

Partial

Reached 49% of the predicted growth at its peak, without hitting the target.

At window close

+5.1%

realized, from the publication price to the last close inside the window

Peak gain

+7.4%

peak, from the publication price — not a realized return

S&P 500, same window

+3.3%

SPY over the identical days, dividend-adjusted

Window close

$235.99

last close inside the window, ended January 19, 2026

Peak price

$241.26

peak on January 13, 2026 — not a realized return

Days to target

—

The thesis — published October 21, 2025

Predicted growth

+15%

over the measurement window

Target price

$257.95

the price the thesis aimed for

Entry zone

$221.39 – $225.38

the fair-value band we waited for

Price at publication

$224.61

published October 21, 2025

Confidence

66%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Danaher beat expectations and grew sales 4.4%. The price trend is improving, and more buyers than usual have been active on up days. In a friendly earnings season, its high-quality lab tools can attract fresh money from funds. Buying near recent price lows aims for a steady move over the next 0-3 months toward past highs, while risk stays measured. This balances some mixed backward-looking metrics as momentum rebuilds.

Primary drivers

Latest quarter beat expectations; sales grew 4.4% versus last year
Trend improving with strong recent average price and constructive action
More buyers than usual on up days, showing healthy demand for shares
High-quality lab and diagnostic tools can draw new money from investors

How it played out

DHR: target was not reached by window end

Lyra published DHR on 2025-10-21 at $224.61, with an expected 15% gain toward $257.95 over the short-term window. The thesis pointed to a quarter that beat expectations, 4.4% sales growth versus last year, an improving price trend, stronger buying on up days, and demand for high-quality lab and diagnostic tools.

Inside the window, DHR rose but did not reach the target. The peak was $241.26 on 2026-01-13, a 7.4% gain. It ended the window at $235.99 on 2026-01-19. The thesis partially played out on direction, but it missed the published target. It never got there.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All DHR signals